How can Pharma Navigate Turbulent Seas? Find out in our World Preview Webinar
The Evaluate World Preview report is a staple of the pharma calendar. The 2025 edition has just been published, marking the 18th year of providing forecast and trend insights to decision makers across the industry. If you’re not familiar with the World Preview, I recommend taking a look. Not only does it provide a wealth […]
Three Things we Learned in our Biotech Commercialization Webinar
The board at Verona Pharma was taking the steps necessary to take its chronic obstructive pulmonary disorder (COPD) drug to market years ahead of its launch in 2024. This long term view was one of the details shared by Verona’s Chief Commercial Officer, Chris Martin during our recent webinar “Going Solo: What’s Driving the Biotech […]
A Blueprint for Biotech Commercialization?
“Think twice, and twice more, before launching your own drug. It is unimaginably difficult and complex”. Those were the words of a biotech CEO I interviewed more than a decade ago. The advice remains sound. Yet today there are tailwinds encouraging more biotechs to take their prized assets all the way to market. (And let’s […]
Three Things we Learned in our “First to Market Myth” Webinar
It is a truth universally acknowledged that a new market in possession of unmet need will reward its first entrant with commercial advantage. Except, that “truth” may be somewhat overstated. This was the topic of our recent webinar, “The First to Market Myth: What Really Drives Launch Success?”. During the session, Evaluate consultants Mark Lansdell, […]
Should Pharma Companies Really Race to be First to Market?
For Portfolio Strategy teams in pharma companies, there is a constant juggling act to ensure that the right therapies are being prioritized for the right indications. This requires a clear understanding of the potential market size, payer perspectives and competitive environment. With the right data and insight, you can plan your go-to-market approach – and […]
Three Things we Learned in our Mastering Long-Range Planning Processes Webinar
Our webinar on Long-Range Planning (LRP) forecasting took place recently and – as always – our experts Andrew Ward and Amanda Randall were on fine form. Full disclosure – this was our second webinar on this topic. You can catch up with part one – The Forecaster’s Guide to Long Range Planning here. The session […]
The High-Stakes Landscape for Competitive Intelligence
Competitive Intelligence teams occupy quite a unique place in a biopharma organization. They collaborate with a really wide range of stakeholders – sales, regulatory, forecasting and many more. This gives CI professionals insight into countless strategic initiatives across the company. But it also means trying to support a lot of different, sometimes almost contradictory needs. […]
Mastering Long-Range Planning: From Challenges to Actionable Solutions
Are you in the midst of yet another challenging Long Range Planning (LRP) cycle and wondering if there is a better way? If the answer is yes, may I suggest you register for our upcoming webinar. In our first webinar on this topic, we talked about some of the biggest challenges in LRP. In this […]
The Pharma Files: What Have you Missed?
As you probably know, Evaluate has an incredibly rich and comprehensive set of data and insight about the pharma market. This means we’re able to produce some really valuable reports, webinars and articles that provide insight around the most exciting areas of the industry. And we create rather a lot of them, which can make […]
Is it Time to Rethink Orphan Drugs?
If you follow Evaluate’s regular white papers and blogs, you may be familiar with our annual report that investigates the state of the orphan drug market. I’ve been involved in analyzing that data for the past three years, and have just finished the process for this year’s report which will be published soon. One of […]
